Abstract
DCs are recognized as the pivotal group of lymphocytes, which induce a variety of antitumor immune responses. Enduring professional antigen presenting cells, DCs eminence to induce adaptive antitumor immune response was exploited, which showed promising results in DCs-based phased clinical studies. Nevertheless, DCs also influence other immune cells to induce multiple arms of immune system to cure cancer. Recently, direct cytotoxic capacity of DCs has been demonstrated in several studies. Altogether DCs hold a strong link between innate and adaptive immune responses. DCs are known to kill tumor cells, phagocytose immunogenic substrates and present a wide variety of antigens to prime T cells to induce concerted antitumor responses. These functional aspects of DCs are dependent on the receptors that participate in the stimulation of DCs. In this review, we have discussed these receptors that are known to induce direct cytotoxicity as well as the receptors that greatly influence their antigen presentation functions. Thus DCs are turning out to be an important cell type in cancer immunotherapy.
Keywords: Dendritic cell receptors, antitumor response, apoptosis, tumor therapy
Current Molecular Medicine
Title: Dendritic Cells and their Receptors in Antitumor Immune Response
Volume: 9 Issue: 6
Author(s): Raghvendra M. Srivastava and Ashok Khar
Affiliation:
Keywords: Dendritic cell receptors, antitumor response, apoptosis, tumor therapy
Abstract: DCs are recognized as the pivotal group of lymphocytes, which induce a variety of antitumor immune responses. Enduring professional antigen presenting cells, DCs eminence to induce adaptive antitumor immune response was exploited, which showed promising results in DCs-based phased clinical studies. Nevertheless, DCs also influence other immune cells to induce multiple arms of immune system to cure cancer. Recently, direct cytotoxic capacity of DCs has been demonstrated in several studies. Altogether DCs hold a strong link between innate and adaptive immune responses. DCs are known to kill tumor cells, phagocytose immunogenic substrates and present a wide variety of antigens to prime T cells to induce concerted antitumor responses. These functional aspects of DCs are dependent on the receptors that participate in the stimulation of DCs. In this review, we have discussed these receptors that are known to induce direct cytotoxicity as well as the receptors that greatly influence their antigen presentation functions. Thus DCs are turning out to be an important cell type in cancer immunotherapy.
Export Options
About this article
Cite this article as:
Srivastava M. Raghvendra and Khar Ashok, Dendritic Cells and their Receptors in Antitumor Immune Response, Current Molecular Medicine 2009; 9 (6) . https://dx.doi.org/10.2174/156652409788970715
DOI https://dx.doi.org/10.2174/156652409788970715 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Mechanistic Insight of Drug Resistance with Special Focus on Iron in Estrogen Receptor Positive Breast Cancer
Current Pharmaceutical Biotechnology Epidermal Stem Cells - Role in Normal, Wounded and Pathological Psoriatic and Cancer Skin
Current Stem Cell Research & Therapy α7 nAChR in Airway Respiratory Epithelial Cells
Current Drug Targets Channel-Like Functions of the 18-kDa Translocator Protein (TSPO): Regulation of Apoptosis and Steroidogenesis as Part of the Host-Defense Response
Current Pharmaceutical Design Brain Tumour Stem Cells: Implications for Cancer Therapy and Regenerative Medicine
Current Stem Cell Research & Therapy Spinal Microvascular Expression of PV-1 is Associated with Inflammation, Perivascular Astrocyte Loss, and Diminished EC Glucose Transport Potential in Acute SCI
Current Neurovascular Research Targeted Drug Delivery to Cancer Stem Cells through Nanotechnological Approaches
Current Stem Cell Research & Therapy Multidrug Transporters as Drug Targets
Current Drug Targets Protein Kinase CK2 in Human Diseases
Current Medicinal Chemistry Resveratrol as a Chemopreventive Agent: A Promising Molecule for Fighting Cancer
Current Drug Targets STAT3: A Molecular Target for Cancer Whose Time Has Come
Current Signal Transduction Therapy TRP Channels and Cancer: New Targets for Diagnosis and Chemotherapy
Endocrine, Metabolic & Immune Disorders - Drug Targets Functions of Antimicrobial Peptides in Vertebrates
Current Protein & Peptide Science Purines and Pyrimidines: Metabolism, Function and Potential as Therapeutic Options in Neurodegenerative Diseases
Current Protein & Peptide Science MicroRNA Targeting as a Therapeutic Strategy Against Glioma
Current Molecular Medicine Carrier Deformability in Drug Delivery
Current Pharmaceutical Design Potential Gene Therapy Strategies for Cancer Stem Cells
Current Gene Therapy Update of Targeted Therapy-Induced Hypertension: Basics for Non-Oncology Providers
Current Hypertension Reviews Pulmonary Hypertension and Systemic Diseases
Current Drug Targets - Inflammation & Allergy Study of 5-Fluorouracil Loaded Chitosan Nanoparticles for Treatment of Skin Cancer
Recent Patents on Nanotechnology